The race is not over, but regulators and product teams are betting on gel-based electrolytes now.

The “this doesn’t feel real” moment Knicks supporters have waited for arrived, and it changes how decisions get made next.

A Data Center Watch report shows grassroots opposition is forcing the AI build cycle to reroute or pause.

A London biotech is testing an oral drug to make blood-cancer immunotherapy safer by preventing CRS in NHS patients.

New York turns 37 first-half points into an identity-defining defensive second half, winning their first title in 53 years.

Billions Club era hits a new peak: Spotify and Amazon cite top single-day and 24-hour global debuts after June 12.

First-day trading for the aerospace and AI company turned an unprecedented IPO into a $2tn-style market reckoning for public-market readiness.

The SPCX listing breaks records, but Japanese household investors quietly took a meaningful chunk of the biggest payday ever.

The IPO lands on Nasdaq as critics question Musk’s near-absolute ownership, and the filings force boards to look hard.

A $12B funding round values the physical AI startup at $41B, aiming to automate heavy engineering and drug design.

SpaceX moves from rumor to price point: $135 per share signals a new bar for private-market exits and public-market gravity.

Trading starts June 12 at $135, but analysts are split over a $72-per-share “option premium” on orbital AI dreams.